Lyra Therapeutics Q2 2025 net loss $7.4M; cash $29.8M; ENLIGHTEN 2 Phase 3 met primary endpoint

Lyra Therapeutics, Inc.

2025-Q2 EPS reported -$12.00 revenue$366,000

Net loss Q2 2025 $7.4M vs $48.1M YoY due to lower R&D and no impairment charges.
Cash $29.8M at June 30, 2025; $5.0M gross financing extends runway into Q3 2026.
ENLIGHTEN 2 Phase 3 met primary endpoint: 3CS improvement -1.13 (p=0.0078) at week 24; key secondary endpoints also met.
Preparing for Type C meeting with FDA in H2 2025 to align on NDA submission path for LYR-210 in CRS without nasal polyps.
Completed 1-for-50 reverse stock split in May; regained Nasdaq minimum bid compliance.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-107339
form_type: 8-K
ticker: LYRA
cik: 0001327273
company_name: Lyra Therapeutics, Inc.
filed_at: 2025-08-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.685787+00:00
generated_at: 2026-05-17T14:21:31.399420+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-107339
json_url: https://secwatch.observer/filing/0000950170-25-107339.json
markdown_url: https://secwatch.observer/filing/0000950170-25-107339.md
text_url: https://secwatch.observer/filing/0000950170-25-107339.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017025107339/0000950170-25-107339-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017025107339/lyra-20250812.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-107339

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.